Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2021

Disaggregation of Revenue

Revenue for the years ended December 31, 2021, 2020 and 2019 was as follows:

	For the Years Ended December 31,
	2021		2020		2019
	(Amounts in thousands)
Product revenue	$	670,319	$	366,136	$	270,097
Royalty and other income		215		124		148
Total revenue	$	670,534	$	366,260	$	270,245

Revenue from Significant Customers

Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows (amounts in thousands):

	For the Years Ended December 31,
	2021		2020		2019
Pfizer Inc.	$	68,273	N/A		N/A
MilliporeSigma	N/A		$	39,511	$	36,190
Cytiva	N/A		N/A		$	31,441

Summary of Receivables and Deferred Revenue from Contracts with Customers

The following table provides information about receivables and deferred revenue from contracts with customers as of December 31, 2021 (amounts in thousands):

	2021		2020
Balances from contracts with customers only:
Accounts receivable	$	117,420	$	71,257
Deferred revenue (included in accrued liabilities in    the consolidated balance sheets)	$	14,848	$	15,318
Revenue recognized during years presented relating to:
The beginning deferred revenue balance	$	13,708	$	3,361